A viral kinetic study using pegylated interferon alfa-2b and/or lamivudine in patients with chronic hepatitis B/HBeAg negative

Hepatology

Volumn 42, Issue 1, 2005, Pages 77-85

  Sypsa, Vassiliki Anastasia ^a   Mimidis, Konstantinos ^b   Tassopoulos, Nicholas C ^c   Chrysagis, Dimitrios ^d   Vassiliadis, Themistoklis ^e   Moulakakis, Antonios ^f   Raptopoulou, Maria ^g   Haida, Caterina ^a   Hatzakis, Angelos ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b Military Hospital of Alexandroupolis   (Greece)

^c West Attica Hospital   (Greece)

^d Loimodon Hospital   (Greece)

^e Aristotle University of Thessaloniki   (Greece)

^f HIPPOKRATION HOSPITAL   (Greece)

^g ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS B(E) ANTIGEN; LAMIVUDINE; PEGINTERFERON ALPHA2B;

ADULT; AGED; ANTIVIRAL ACTIVITY; ARTICLE; BINDING KINETICS; CHRONIC HEPATITIS; COMBINATION CHEMOTHERAPY; DRUG POTENCY; FEMALE; HALF LIFE TIME; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HUMAN TISSUE; IMMUNE RESPONSE; MAJOR CLINICAL STUDY; MALE; OSCILLATION; PRIORITY JOURNAL; VIRUS INFECTION; VIRUS LOAD;

ADULT; ANTIVIRAL AGENTS; BIOMECHANICS; FEMALE; HEPATITIS B E ANTIGENS; HEPATITIS B, CHRONIC; HUMANS; INTERFERON ALFA-2A; LAMIVUDINE; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; POLYETHYLENE GLYCOLS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 21344469906     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.20738     Document Type: Article

References (21)

1. Cooksley WG, Piratvisuth T, Lee SD, Mahachai V, Chao YC, Tanwandee T, et al. Peginterferon alpha-2a (40 kDa): an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B. J Viral Hepatol 2003; 10:298-305.
2. Cooksley WG. Treatment with interferons (including pegylated interferons) in patients with hepatitis B. Semin Liver Dis 2004; 24(Suppl 1):45-53.
3. Marcellin P, Lau GK, Bonino F, Farci P, Hadziyannis S, Jin R, et al. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2004; 351:1206-1217.
4. van Zonneveld M, Hansen BE, Niesters HGM, de Man RA, Schalm SW, Janssen HLA. Viral dynamics during PEG-interferon alone and in combination with lamivudine [Abstract]. J Hepatol 2004:40(Suppl 1):446.
5. Perelson AS, Neumann AU, Markowitz M, Leonard JM, Ho DD. HIV-1 Dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science 1996;271:1582-1586.
6. Perelson AS, Essunger P, Cao Y, Vesanen M, Hurley A, Saksela K, et al. Decay characteristics of HIV-1 infected compartments during combination therapy. Nature 1997;387:188-191.
7. Neumann AU, Lam NP, Dahari H, Gretch DR, Wiley TE, Layden TJ, et al. Hepatitis C viral dynamics in-vivo and the antiviral efficacy of interferon-α therapy. Science 1998;282:103-107.
8. Nowak MA, Bonhoeffer S, Hill AM, Boehme R, Thomas HC, McDade H. Viral dynamics in hepatitis B virus infection. Proc Natl Acad Sci U S A 1996;93;4398-4402.
9. Tsiang M, Rooney JF, Toole JJ, Gibbs CS. Biphasic clearance kinetics of hepatitis B virus from patients during adefovir dipivoxil therapy. HEPATOLOGY 1999;29:1863-1869.
10. Lau GK, Tsiang M, Hou J, Yuen S, Carman WF, Zhang L, et al. Combination therapy with lamivudine and famciclovir for chronic hepatitis B-infected Chinese patients: a viral dynamics study. HEPATOLOGY 2000;32: 394-399.
11. Zeuzem S, de Man RA, Honkoop P, Roth WK, Schalm SW, Schmidt JM. Dynamics of hepatitis B virus infection in vivo. J Hepatol 1997;27:431-436.
12. Lewin SR, Ribeiro RM, Walters T, Lau GK, Bowden S, Locarnini S, et al. Analysis of hepatitis B viral load decline under potent therapy: complex decay profiles observed. HEPATOLOGY 2001;34:1012-1020.
13. Wolters LM, Hansen BE, Niesters HG, de Man RA. Viral dynamics in chronic hepatitis B patients treated with lamivudine, lamivudine-famciclovir or lamivudine-ganciclovir. Eur J Gastroenterol Hepatol 2002;14:1007-1011.
14. Wolters LM, Hansen BE, Niesters HG, DeHertogh D, de Man RA. Viral dynamics during and after entecavir therapy in patients with chronic hepatitis B. J Hepatol 2002;37:137-l44.
15. Wolters LM, Hansen BE, Niesters HG, Levi-Drummer RS, Neumann AU, Schalm SW, et al. The influence of baseline characteristics on viral dynamic parameters in chronic hepatitis B patients treated with lamivudine. J Hepatol 2002;37:253-258.
16. Wolters LM, Hansen BE, Niesters HG, Zeuzem S, Schalm SW, de Man RA. Viral dynamics in chronic hepatitis B patients during lamivudine therapy. Liver 2002;22:121-126.
17. Colombatto P, Bizzarri R, Civitano L, Oliveri F, Bonino F, Germanidis G, et al. A new bio-mathematical model to describe the dynamics of HBV-DNA and infected hepatocytes in HBEAG-negative/anti-HBE-positive chronic hepatitis B patients treated with peginterferon alfa-2a (40kd) (PEGASYS (R)), lamivudine, or PEGASYS (R) plus lamivudine combination therapy [Abstract]. J Hepatol 2004;40(Suppl 1):421.
18. Powers KA, Dixit NM, Ribeiro RM, Golia P, Talal AH, Perelson AS. Modeling viral and drug kinetics: hepatitis C virus treatment with pegylated interferon alfa-2b. Semin Liver Dis 2003;23 (Suppl 1):13-18.
19. Paraskevis D, Haida C, Tassopoulos N, Raptopoulou M, Tsantoulas D, Papachristou H, et al. Development and assessment of a novel real-time PCR assay for quantitation of HBV DNA. J Virol Methods 2002;103:201-212.
20. Zeuzem S, Welsch C, Herrmann E. Pharmacokinetics of peginterferons. Semin Liver Dis 2003;23(Suppl 1):23-28.
21. Muggeo VM. Estimating regression models with unknown break-points. Stat Med 2003;22:3055-3071.